The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Dose-escalation studies of mesenchymal stromal cell therapy for decompensated liver cirrhosis: phase Ia/Ib results and immune modulation insights
Open accessAbstract
Decompensated liver cirrhosis (DLC) is characterized by severe liver dysfunction and immune dysregulation, posing significant treatment challenges. Mesenchymal stromal cell (MSC) therapy has shown promise in DLC treatment, but the optimal dosing strategies and dose-dependent therapeutic mechanisms in humans remain unclear, limiting its clinical application. We conducted sequential Phase Ia/Ib trials using a single-arm, dose-escalation design to evaluate the safety and tolerability of MSC therapy in DLC patients while also exploring its immunomodulatory effects and gathering preliminary therapeutic signals. In Phase Ia, four dose cohorts received a single dose of MSCs: 5.0 × 10⁷, 1.0 × 10⁸, 1.5 × 10⁸, and 2.0 × 10⁸ cells. Patients were followed up on Days 3, 7, 14, and 28. Multiomics analyses, including single-cell RNA sequencing and cytometry by time of flight, were conducted to perform exploratory mechanistic analyses investigating immune cell dynamics and dose-dependent responses. Building on these findings, Phase Ib included two dose cohorts, each of which received three doses of MSCs administered one week apart: 1.0 × 10⁸ and 2.0 × 10⁸ cells per dose. Patients were followed up on Days 7, 14, 21, and 28 to further evaluate the safety and feasibility of multiple-dose regimens. The trials were registered at ClinicalTrials.gov (NCT05227846 and NCT05984303). MSC therapy demonstrated good safety and tolerability in both Phase Ia and Phase Ib trials, with no severe adverse events, dose-limiting toxicities, or serious unexpected adverse reactions observed up to Day 28. Multi-omics analyses revealed that higher MSC doses elicited stronger immunomodulatory effects, particularly by modulating monocyte subsets. In particular, myxovirus resistance 1 positive (MX1 + ) monocytes, a key monocyte population, exhibited dose-dependent changes and were identified as a mediator of MSC-induced immunomodulation. These effects were sustained for up to seven days post-treatment but diminished by Day 14. Preliminary clinical signals included improvements in Child–Pugh scores, Model for End-Stage Liver Disease scores, liver function markers, and quality-of-life metrics, particularly in the higher-dose and multiple-dose groups. This study demonstrates the safety and tolerability of MSC therapy in patients with DLC and provides the first human-based evidence on the dose‒effect relationship and optimal administration regimens. The identification of MX1 + monocytes as a critical mediator highlights the potential of MSC therapy to modulate immune dysfunction in DLC. These findings offer valuable insights for optimizing MSC therapy and informing the design of future efficacy-focused clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrated analysis of multimodal single-cell data
Hao, Y., Hao, S., Andersen-Nissen, E., Mauck, W. M., Zheng, S., Butler, A., Lee, M. J., Wilk, A. J., Darby, C., Zagar, M., et al. (2020) · doi:10.1101/2020.10.12.335331 · Cited by 15,508
Inference and analysis of cell-cell communication using CellChat
Jin, S., Guerrero-Juarez, C. F., Zhang, L., Chang, I., Ramos, R., Kuan, C.-H., Myung, P., Plikus, M. V., & Nie, Q. (2021) · Nature Communications · doi:10.1038/s41467-021-21246-9 · Cited by 8,409
McGinnis, C. S., Murrow, L. M., & Gartner, Z. J. (2019) · Cell Systems · doi:10.1016/j.cels.2019.03.003 · Cited by 4,521
The single-cell transcriptional landscape of mammalian organogenesis
Cao, J., Spielmann, M., Qiu, X., Huang, X., Ibrahim, D. M., Hill, A. J., Zhang, F., Mundlos, S., Christiansen, L., Steemers, F. J., et al. (2019) · Nature · doi:10.1038/s41586-019-0969-x · Cited by 4,490
Slingshot: cell lineage and pseudotime inference for single-cell transcriptomics
Street, K., Risso, D., Fletcher, R. B., Das, D., Ngai, J., Yosef, N., Purdom, E., & Dudoit, S. (2018) · BMC Genomics · doi:10.1186/s12864-018-4772-0 · Cited by 3,159
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12150 · Cited by 2,751
Ginès, P., Krag, A., Abraldes, J. G., Solà, E., Fabrellas, N., & Kamath, P. S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01374-x · Cited by 1,663
Cirrhosis-associated immune dysfunction: Distinctive features and clinical relevance
Albillos, A., Lario, M., & Álvarez-Mon, M. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.08.010 · Cited by 1,242
Stem cell-based therapy for human diseases
Hoang, D. M., Pham, P. T., Bach, T. Q., Ngo, A. T. L., Nguyen, Q. T., Phan, T. T. K., Nguyen, G. H., Le, P. T. T., Hoang, V. T., Forsyth, N. R., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01134-4 · Cited by 1,074 · cited 1×
“12 16 – 18 However, the clinical results remain mixed, with some studies reporting limited or no signi fi cant bene fi ts. 19,20 These variations may stem from differences in MSC dosing, administration intervals, inclusion criteria, and outcome de fi nitions, which pose challenges to standardizing MSC…”
Global epidemiology of cirrhosis — aetiology, trends and predictions
Huang, D. Q., Terrault, N. A., Tacke, F., Gluud, L. L., Arrese, M., Bugianesi, E., & Loomba, R. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00759-2 · Cited by 839
Research works printed but not linked: 1
- Feio-Azevedo, R. et al. Distinct immunometabolic signatures in circulating immune cells define disease outcome in acute-on-chronic liver failure. Hepatology 81, 509–522 (2024). · DOI
Cited by
Choi, S., & Jeong, J. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020619 · Cited by 12
Mesenchymal stem cell therapy for end-stage liver disease: adversity and opportunity
Li, S., Wang, Y., Li, S., Zhu, Y., Du, Y., Zheng, X., & Wu, J. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04788-3 · Cited by 6
Effects of Different Forms of Selenium in Human Umbilical Cord Mesenchymal Stem Cells
Ni, B., Li, C., Lin, H., Chen, W., Xu, R., Li, H. ‐., Chen, X., Lu, J., & Yang, F. (2025) · Biomedicines · doi:10.3390/biomedicines13122861 · Cited by 2
Wang, S., Wang, Y., Zhang, S., Li, T., Zhou, X., & Chen, L. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1691224 · Cited by 2
Application of stem cells in the precise diagnosis and treatment of liver diseases
Wang, Y.-X., Ren, Y.-N., Zhang, S.-S., Sun, S., Xu, M.-Y., Wei, T., & Zhang, L.-S. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i46.114415 · Cited by 2
Metadata
- Authors
- Shi, L., Zhang, Z., Mei, S., Wang, Z., Xu, Z., Yao, W., Liu, L., Yuan, M., Pan, Y., Zhu, K., Liu, K., Meng, F., Sun, J., Liu, W., Xie, X., Dong, T., Huang, L., Meng, F., Fu, J.-L., Li, Y., Zhang, C., Fan, X., Shi, M., Zhang, Y., Li, Y., Xie, W.-F., Zhang, P., & Wang, F.-S.
- Affiliations
- Chinese PLA General Hospital (CN)
- Shanghai Jiao Tong University (CN)
- Hubei University of Technology (CN)
- Second Military Medical University (CN)
- Capital Medical University (CN)
- Corresponding author
- Shi, Lei
- Zhang, Peng
- Wang, Fu-Sheng
- ORCID
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2025-07-29
- Volume
- 10
- Issue
- 1
- Pages
- 238-238
- ISSN
- 2059-3635 (ISSN-L)
- PMC
- PMC12304480
- OpenAlex
- W4412726720
- Cited by
- 16
- References
- 58
- Citations by year
- 2026: 12 · 2025: 4
- FWCI
- 10.28
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Children's Research Centre
- Sun Yat-sen University
- Sichuan University
- General Hospital of People’s Liberation Army
- NIH Clinical Center
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- mesenchymal stem cells, cell therapy, decompensated cirrhosis, dose escalation, immunomodulation, monocyte subsets, safety and tolerability, multiple-dose regimen, Child-Pugh score, MELD score, liver function, single-cell RNA sequencing, multi-omics, liver fibrosis
- MeSH terms
- Adult, Aged, Female, Humans, Liver Cirrhosis, Male, Middle Aged, Mesenchymal Stem Cell Transplantation, Immunomodulation, Mesenchymal Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dose-escalation studies of mesenchymal stromal cell therapy for decompensated liver cirrhosis: phase Ia/Ib results and immune modulation insights. https://app.cochat.ai/papers/10.1038/s41392-025-02318-4
- The paper
- Shi, L., Zhang, Z., Mei, S., Wang, Z., Xu, Z., Yao, W., Liu, L., Yuan, M., Pan, Y., Zhu, K., Liu, K., Meng, F., Sun, J., Liu, W., Xie, X., Dong, T., Huang, L., Meng, F., Fu, J.-L., . . . Wang, F.-S. (2025). Dose-escalation studies of mesenchymal stromal cell therapy for decompensated liver cirrhosis: phase Ia/Ib results and immune modulation insights. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-025-02318-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.